Patents by Inventor Laurence A. Lasky
Laurence A. Lasky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120328632Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: December 21, 2011Publication date: December 27, 2012Applicant: Genentech, Inc.Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Publication number: 20080241143Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: September 26, 2007Publication date: October 2, 2008Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Patent number: 7264817Abstract: Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of truncated, membrane-free derivatives of a membrane-bound polypeptide from the pathogen. These polypeptides when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.Type: GrantFiled: June 2, 1995Date of Patent: September 4, 2007Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Laurence A. Lasky
-
Publication number: 20060229435Abstract: DNA isolates coding for the lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.Type: ApplicationFiled: January 5, 2006Publication date: October 12, 2006Applicant: Genentech, Inc.Inventors: Laurence Lasky, Scott Stachel, Steven Rosen, Mark Singer, Ted Yednock
-
Patent number: 6887705Abstract: This invention concerns new PSTPIP polypeptides which are bound by and dephosphorylated by the PEST family of protein tyrosine phosphatases. The invention specifically concerns native murine PSTPIP polypeptides and their homologues in other mammals, and their functional derivatives. The invention further relates to nucleic acids encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Methods for inducing the plymerization of actin monomers in eukaryotic cells and assays for identifying antagonists and agonists of the PSTPIP polypeptides of the present invention are also provided.Type: GrantFiled: January 30, 1998Date of Patent: May 3, 2005Assignee: Genentech, Inc.Inventors: Laurence A. Lasky, Donald J. Dowbenko
-
Publication number: 20040141966Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: January 15, 2003Publication date: July 22, 2004Applicant: Genentech, Inc.; The Regents of the University of CaliforniaInventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Publication number: 20040014172Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: ApplicationFiled: March 7, 2003Publication date: January 22, 2004Applicant: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Publication number: 20030148264Abstract: The invention pertains to a method of identifying PDZ interacting polypeptides, said polypeptides, and uses of said polypeptides.Type: ApplicationFiled: July 3, 2002Publication date: August 7, 2003Applicant: GENENTECH, INC.Inventors: Heike A. Held, Laurence A. Lasky, Richard P. Laura, Sachdev S. Sidhu, Wai Lee Tan Wong, Yan Wu
-
Publication number: 20030143220Abstract: Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.Type: ApplicationFiled: March 12, 2002Publication date: July 31, 2003Applicant: Genentech, Inc.Inventors: Daniel J. Capon, Laurence A. Lasky
-
Patent number: 6534285Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: GrantFiled: April 12, 2000Date of Patent: March 18, 2003Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Patent number: 6406697Abstract: Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.Type: GrantFiled: August 5, 1997Date of Patent: June 18, 2002Assignee: Genentech, Inc.Inventors: Daniel J. Capon, Laurence A. Lasky
-
Patent number: 6238902Abstract: This invention concerns new non-receptor protein tyrosine phosphatases of the hematopoietic stem cells (PTP HSC). The invention specifically concerns native murine and human PTP HSCs, their analogs in other mammals, and their functional derivatives. The invention further relates to nucleic acid encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Assays for identifying agonists and antagonists of the native PTP HSCs, methods for expansion of undifferentiated stem cells, and methods for the induction of stem cell differentiation are also within the scope of the invention.Type: GrantFiled: March 20, 1997Date of Patent: May 29, 2001Assignee: Genentech, Inc.Inventors: Jill Cheng, Laurence A. Lasky
-
Patent number: 6117977Abstract: The invention concerns novel members of the endocytic type C lectin family and methods and means for producing them. The native polypeptides of the invention are characterized by containing a signal sequence, a cysteine rich domain, a fibronectin type II domain, 8 type C lectin domains, a transmembrane domain and a cytoplasmic domain. Nucleotide sequences encoding such polypeptides, vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel type C lectins are also within the scope of the invention.Type: GrantFiled: April 24, 1997Date of Patent: September 12, 2000Assignee: Genentech, Inc.Inventors: Laurence A. Lasky, Kai Wu
-
Patent number: 6111073Abstract: This invention concerns new PSTPIP polypeptides which are bound by and dephosphorylated by the PEST family of protein tyrosine phosphatases. The invention specifically concerns native murine PSTPIP polypeptides and their homologues in other mammals, and their functional derivatives. The invention further relates to nucleic acids encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Methods for inducing the polymerization of actin monomers in eukaryotic cells and assays for identifying antagonists and agonists of the PSTPIP polypeptides of the present invention are also provided.Type: GrantFiled: February 6, 1998Date of Patent: August 29, 2000Assignee: Genentech, Inc.Inventor: Laurence A. Lasky
-
Patent number: 6083748Abstract: The present invention is directed to antibodies which specifically bind to a novel .kappa./.mu.-like protein tyrosine phosphatase protein herein designated PTP .lambda. and hybridoma cell lines producing the same.Type: GrantFiled: December 16, 1997Date of Patent: July 4, 2000Assignee: Genentech, Inc.Inventors: Jill Cheng, Laurence A. Lasky
-
Patent number: 6040437Abstract: This invention concerns new PSTPIP polypeptides which are bound by and dephosphorylated by the PEST family of protein tyrosine phosphatases. The invention specifically concerns native murine PSTPIP polypeptides and their homologues in other mammals, and their functional derivatives. The invention further relates to nucleic acids encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Methods for inducing the polymerization of actin monomers in eukaryotic cells and assays for identifying antagonists and agonists of the PSTPIP polypeptides of the present invention are also provided.Type: GrantFiled: September 29, 1997Date of Patent: March 21, 2000Assignee: Genentech, Inc.Inventors: Laurence A. Lasky, Donald J. Dowbenko
-
Patent number: 5976852Abstract: This invention concerns novel receptor protein tyrosine phosphatase polypeptides. Specifically, this invention concerns the novel receptor protein tyrosine phosphatase .lambda. which is related to the homotypically adhering receptor protein tyrosine phosphatases .kappa. and .mu.. The invention further relates to analogs of these polypeptides in other mammals, functional derivatives thereof, antibodies which are capable of specifically binding to these polypeptides, nucleic acids encoding these polypeptides, vectors containing and capable of expressing such nucleic acid and recombinant host cells transformed with such nucleic acid. Methods for the recombinant production of these receptor protein tyrosine phosphatase polypeptides and assays for identifying agonists and antagonists of these polypeptides are also within the scope of the invention.Type: GrantFiled: December 19, 1996Date of Patent: November 2, 1999Assignee: Genentech, Inc.Inventors: Jill Cheng, Laurence A. Lasky
-
Patent number: 5928887Abstract: This invention concerns novel receptor protein tyrosine phosphatase polypeptides. Specifically, this invention concerns the novel receptor protein tyrosine phosphatase .lambda. which is related to the homotypically adhering receptor protein tyrosine phosphatases .kappa. and .mu.. The invention further relates to analogs of these polypeptides in other mammals, functional derivatives thereof, antibodies which are capable of specifically binding to these polypeptides, nucleic acids encoding these polypeptides, vectors containing and capable of expressing such nucleic acid and recombinant host cells transformed with such nucleic acid. Methods for the recombinant production of these receptor protein tyrosine phosphatase polypeptides and assays for identifying agonists and antagonists of these polypeptides are also within the scope of the invention.Type: GrantFiled: December 16, 1997Date of Patent: July 27, 1999Assignee: Genentech, Inc.Inventors: Jill Cheng, Laurence A. Lasky
-
Patent number: 5853978Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: GrantFiled: July 29, 1994Date of Patent: December 29, 1998Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Patent number: 5851533Abstract: Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of glycoproteins of the organism, that have been prepared via recombinant means, and preferably C-truncated versions thereof. These glycoproteins when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.Type: GrantFiled: December 15, 1994Date of Patent: December 22, 1998Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Laurence A. Lasky